SEC INSIDER TRANSACTIONS

THERMO FISHER SCIENTIFIC INC. (TMO) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

TMO · THERMO FISHER SCIENTIFIC INC.

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 40 filings · fetched 2026-11-13T20:19:33Z

Recent reported activity

0purchase rows on this page

25sale rows on this page

165matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F7	S Sale (market/private)Common Stock · Non-derivative	522D	589.52	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F6	S Sale (market/private)Common Stock · Non-derivative	228D	587.64	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F5	S Sale (market/private)Common Stock · Non-derivative	945D	586.52	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F4	S Sale (market/private)Common Stock · Non-derivative	530D	585.44	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	1,035D	584.41	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F13	S Sale (market/private)Common Stock · Non-derivative	302D	583.35	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F12	S Sale (market/private)Common Stock · Non-derivative	113D	581.85	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F11	S Sale (market/private)Common Stock · Non-derivative	113D	580.71	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F10	S Sale (market/private)Common Stock · Non-derivative	114D	579.26	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	94D	577.37	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F9	S Sale (market/private)Common Stock · Non-derivative	7D	593.32	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F8	S Sale (market/private)Common Stock · Non-derivative	29D	590.77	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F7	S Sale (market/private)Common Stock · Non-derivative	32D	589.51	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F6	S Sale (market/private)Common Stock · Non-derivative	12D	587.64	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F5	S Sale (market/private)Common Stock · Non-derivative	58D	586.53	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F4	S Sale (market/private)Common Stock · Non-derivative	30D	585.42	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	63D	584.4	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	18D	583.37	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	2D	581.86	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	5D	581.85	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	3D	580.72	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	4D	580.71	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	2D	579.27	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	4D	579.26	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	6D	577.37	Direct	Form 4 ↗0001216055-26-000009

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.